Research

Halo Therapeutics was founded to acquire and develop a powerful anti-fibrotic drug that shows promise as a treatment for Duchenne and other orphan diseases. In animal studies, halofuginone has delayed and in some cases even reversed fibrosis of the muscles, a major factor in the downstream pathology of Duchenne. The sole owners of Halo Therapeutics are Charley’s Fund and an affiliate of the Nash Avery Foundation, putting development of this molecule squarely in the hands of aggressive Duchenne families.